FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1789-1792 April 23, 2009 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: In her letter to the editor, Wysowski (Jan. 1 issue)¹ notes that the Food and Drug Administration (FDA) received reports of 23 cases of esophageal cancer in patients who had received oral bisphosphonates, and she calls for studies that investigate whether bisphosphonate use is associated with an increased risk of this cancer. The reported cases of esophageal cancer occurred after a relatively short duration of use, with a median time to diagnosis of 2.1 years.

Using data from national registers (1995 through 2005), we individually matched 13,678 patients with fracture who had filled more than one prescription . . . [Full Text of this Article]

Related Letters:

Reports of Esophageal Cancer with Oral Bisphosphonate Use
Wysowski D. K.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:89-90, Jan 1, 2009. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.